WB, IHC-P
H
Endogenous
55
Rabbit IgG
#Q9UBF1
51438
Product Information
Product Usage Information
This formulation is ideal for use with technologies requiring specialized or custom antibody labeling, including fluorophores, metals, lanthanides, and oligonucleotides. It is not recommended for ChIP, ChIP-seq, CUT&RUN or CUT&Tag assays. If you require a carrier free formulation for chromatin profiling, please contact us. Optimal dilutions/concentrations should be determined by the end user.
Formulation
Storage
Specificity / Sensitivity
Species Reactivity:
Human
Source / Purification
Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Val75 of human MAGE-C2/CT10 protein.
Background
Cancer/testis antigens (CTAs) are a family of more than 100 proteins whose normal expression is largely restricted to immune privileged germ cells of the testis, ovary, and trophoblast cells of the placenta. Although most normal somatic tissues are void of CTA expression, due to epigenetic silencing of gene expression, their expression is upregulated in a wide variety of human solid and liquid tumors (1,2). As such, CTAs have garnered much attention as attractive targets for a variety of immunotherapy-based approaches to selectively attack tumors (3).
Melanoma-associated antigen-C2/Cancer testis antigen 10 (MAGE-C2/CT10) belongs to the type I MAGE family of proteins. In normal human tissues, MAGE-C2/CT10 expression is nuclear and largely restricted to germline cells of the testis (4). At the molecular level, research studies have demonstrated that MAGE-C2/CT10 physically interacts with and enhances activity of the TRIM28 E3 RING ubiquitin ligase (5,6). MAGE-C2/CT10 has also been shown to interact with and regulate the activity of SCF CRL E3 ubiquitin ligase complexes toward substrates that control cell cycle progression, suggesting a role for MAGE-C2/CT10 in malignant transformation (7). Indeed, MAGE-C2/CT10 is aberrantly expressed in testicular germ cell tumors, prostate carcinoma, hepatocellular carcinoma, and melanoma (8-11). Furthermore, MAGE-C2/CT10 is immunogenic in some tumor types and as a result, there is interest in targeting antigenic epitopes presented in the context of class I MHC alleles using engineered TCRs (12,13).
- Caballero, O.L. and Chen, Y.T. (2009) Cancer Sci 100, 2014-21.
- De Smet, C. et al. (1999) Mol Cell Biol 19, 7327-35.
- Gjerstorff, M.F. et al. (2015) Oncotarget 6, 15772-87.
- Zhuang, R. et al. (2006) Cancer Immun 6, 7.
- Doyle, J.M. et al. (2010) Mol Cell 39, 963-74.
- Yang, B. et al. (2007) Cancer Res 67, 9954-62.
- Hao, J. et al. (2015) Oncotarget 6, 42028-39.
- Bode, P.K. et al. (2011) Mod Pathol 24, 829-35.
- von Boehmer, L. et al. (2011) PLoS One 6, e21366.
- Riener, M.O. et al. (2009) Int J Cancer 124, 352-7.
- Curioni-Fontecedro, A. et al. (2011) PLoS One 6, e21418.
- Ma, W. et al. (2011) Int J Cancer 129, 2427-34.
- Straetemans, T. et al. (2012) Clin Dev Immunol 2012, 586314.
Species Reactivity
Species reactivity is determined by testing in at least one approved application (e.g., western blot).
Applications Key
WB: Western Blotting IHC-P: Immunohistochemistry (Paraffin)
Cross-Reactivity Key
H: human M: mouse R: rat Hm: hamster Mk: monkey Vir: virus Mi: mink C: chicken Dm: D. melanogaster X: Xenopus Z: zebrafish B: bovine Dg: dog Pg: pig Sc: S. cerevisiae Ce: C. elegans Hr: horse GP: Guinea Pig Rab: rabbit All: all species expected
Trademarks and Patents
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.